Klaria Pharma Holding AB (publ.) (STO:KLAR)

Market Cap	198.99M +37.7%
Revenue (ttm)	8.99M +299.7%
Net Income	-38.89M
EPS	-0.21
Shares Out	245.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	848,125
Open	0.7940
Previous Close	0.7920
Day's Range	0.7630 - 0.8350
52-Week Range	0.3960 - 1.3300
Beta	1.20
Analysts	n/a
Price Target	n/a
Earnings Date	May 5, 2026

About STO:KLAR

Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; and Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. The company is also involved in commercialization and sale of...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Employees: 4
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: KLAR

Financial Performance

In 2025, STO:KLAR's revenue was 8.99 million, an increase of 299.69% compared to the previous year's 2.25 million. Losses were -38.89 million, -18.56% less than in 2024.